Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses: 2013-2024

Historic Change in Accured Expenses for Ultragenyx Pharmaceutical (RARE) over the last 12 years, with Dec 2024 value amounting to $47.0 million.

  • Ultragenyx Pharmaceutical's Change in Accured Expenses rose 317.12% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year increase of 88.20%. This contributed to the annual value of $47.0 million for FY2024, which is 5115.54% up from last year.
  • According to the latest figures from FY2024, Ultragenyx Pharmaceutical's Change in Accured Expenses is $47.0 million, which was up 5,115.54% from $901,000 recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Accured Expenses peaked at $79.8 million during FY2022, and registered a low of $901,000 during FY2023.
  • Its 3-year average for Change in Accured Expenses is $42.6 million, with a median of $47.0 million in 2024.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Change in Accured Expenses tumbled by 98.87% in 2023 and then spiked by 5,115.54% in 2024.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Change in Accured Expenses stood at $26.9 million in 2020, then rose by 20.33% to $32.3 million in 2021, then surged by 147.10% to $79.8 million in 2022, then plummeted by 98.87% to $901,000 in 2023, then surged by 5,115.54% to $47.0 million in 2024.